Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lilian van den Brink

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Cancers|April 13, 2023
Pre- and Intraoperative Visualization of GRPR-Expressing Solid Tumors: Preclinical Profiling of Novel Dual-Modality Probes for Nuclear and Fluorescence ImagingMarjolein Verhoeven, Maryana Handula, Lilian van den Brink, et al.
Pharmaceuticals (Basel, Switzerland)|August 26, 2023
Synthesis and Evaluation of ePSMA-DM1: A New Theranostic Small-Molecule Drug Conjugate (T-SMDC) for Prostate CancerErika Murce, Evelien Spaan, Savanne Beekman, et al.
EJNMMI Research|December 24, 2024
In vitro and ex vivo evaluation of preclinical models for FAP-targeted theranostics: differences and relevance for radiotracer evaluationCirce D van der Heide, Joana D Campeiro, Eline A M Ruigrok, et al.
EJNMMI Research|August 2, 2025
Chemotherapy alters radiosensitivity and GRPR expression of prostate and breast cancer cellsTyrillshall S T Damiana, Lilian van den Brink, Lisette W de Kreij-de Bruin, et al.
Frontiers in Oncology|September 18, 2023
GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approachesMarjolein Verhoeven, Eline A M Ruigrok, Geert J L H van Leenders, et al.
Life Sciences|October 31, 2023
Applying HDACis to increase SSTR2 expression and radiolabeled DOTA-TATE uptake: from cells to miceMaria J Klomp, Lilian van den Brink, Peter M van Koetsveld, et al.
Pharmaceutics|January 21, 2022
The Effect of VPA Treatment on Radiolabeled DOTATATE Uptake: Differences Observed In Vitro and In VivoMaria J Klomp, Leo J Hofland, Lilian van den Brink, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Cancers|April 13, 2023
Pre- and Intraoperative Visualization of GRPR-Expressing Solid Tumors: Preclinical Profiling of Novel Dual-Modality Probes for Nuclear and Fluorescence ImagingMarjolein Verhoeven, Maryana Handula, Lilian van den Brink, et al.
Pharmaceuticals (Basel, Switzerland)|August 26, 2023
Synthesis and Evaluation of ePSMA-DM1: A New Theranostic Small-Molecule Drug Conjugate (T-SMDC) for Prostate CancerErika Murce, Evelien Spaan, Savanne Beekman, et al.
EJNMMI Research|December 24, 2024
In vitro and ex vivo evaluation of preclinical models for FAP-targeted theranostics: differences and relevance for radiotracer evaluationCirce D van der Heide, Joana D Campeiro, Eline A M Ruigrok, et al.
EJNMMI Research|August 2, 2025
Chemotherapy alters radiosensitivity and GRPR expression of prostate and breast cancer cellsTyrillshall S T Damiana, Lilian van den Brink, Lisette W de Kreij-de Bruin, et al.
Frontiers in Oncology|September 18, 2023
GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approachesMarjolein Verhoeven, Eline A M Ruigrok, Geert J L H van Leenders, et al.
Life Sciences|October 31, 2023
Applying HDACis to increase SSTR2 expression and radiolabeled DOTA-TATE uptake: from cells to miceMaria J Klomp, Lilian van den Brink, Peter M van Koetsveld, et al.
Pharmaceutics|January 21, 2022
The Effect of VPA Treatment on Radiolabeled DOTATATE Uptake: Differences Observed In Vitro and In VivoMaria J Klomp, Leo J Hofland, Lilian van den Brink, et al.
Pageof 1